Barclays Reiterates an 'Overweight' on Teva Pharmaceutical (TEVA); Stock Lull Creates Opportunity
Tweet Send to a FriendGet Alerts TEVA Hot Sheet
Price: $39.49 +0.36%
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Trade TEVA Now!
Barclays reiterates an 'Overweight' rating on Teva Pharmaceutical (Nasdaq: TEVA), price target $73.
Barclays analyst says, "After a rebound from what we viewed as oversold levels, recent "lull" in stock performance has created an attractive buying opportunity ahead of potential positive catalysts in the coming months, in our opinion. Reiterating our rating and continue to recommend purchase, particularly for long-term investors."
"We are introducing our pro-forma estimates to include Ratiopharm acquisition, with 3Q results representing the first quarter to include a contribution. We expect Teva to meet our and consensus 3Q proforma estimate of $1.27, with the July launch of Effexor XR adding $414M in revs by our estimate, based on IMS scrips trend and stocking est. May witness some 3Q Ratiopharm financial contrib. granularity, a positive & atypical for Teva following an acquisition close. Noteworthy pending potential catalysts: (1) oral laquinimod first P3 trial results in 1Q; (2) Copaxone low-vol version PDUFA date of Jan 1; (3) generic Lovenox approval (anytime)."
FY11 EPS estimate of $4.60 and FY12 increased from $4.86 to $5.25.
To see all the upgrades/downgrades on shares of TEVA, visit our Analyst Ratings page.
Shares are currently trading at $52.64, down $0.19 (-0.36%)
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Barclays analyst says, "After a rebound from what we viewed as oversold levels, recent "lull" in stock performance has created an attractive buying opportunity ahead of potential positive catalysts in the coming months, in our opinion. Reiterating our rating and continue to recommend purchase, particularly for long-term investors."
"We are introducing our pro-forma estimates to include Ratiopharm acquisition, with 3Q results representing the first quarter to include a contribution. We expect Teva to meet our and consensus 3Q proforma estimate of $1.27, with the July launch of Effexor XR adding $414M in revs by our estimate, based on IMS scrips trend and stocking est. May witness some 3Q Ratiopharm financial contrib. granularity, a positive & atypical for Teva following an acquisition close. Noteworthy pending potential catalysts: (1) oral laquinimod first P3 trial results in 1Q; (2) Copaxone low-vol version PDUFA date of Jan 1; (3) generic Lovenox approval (anytime)."
FY11 EPS estimate of $4.60 and FY12 increased from $4.86 to $5.25.
To see all the upgrades/downgrades on shares of TEVA, visit our Analyst Ratings page.
Shares are currently trading at $52.64, down $0.19 (-0.36%)
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Hewlett-Packard (HPQ) Q2 Performance Wins Praise on Wall Street; Jefferies Raises to Hold
- Toll Bros. (TOL) Q2 Solid but Not Much Better Than Peers
- Topeka Capital Starts Cavium Networks (CAVM) at Hold
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
